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Evaluation of 3-benzylthiomethyl chlorothiazide 
A new oral diuretic 
A clinical evaluation is presented of the relative diuretic effectiveness of benzylthiomethyl 
chlorothiazide and hydrochlorothiazide in 17 edematous patients. Comparing single 100 mg. 
doses of each drug, benzylthiomethyl chlorothiazide is about 85 per cent as effective 
as hydrochlorothiazide. 
Robert L. Hauman, A.B., and John M. Weller, M.D. Ann Arbor, Mich. 
Department of Internal Medicine, The University of Michigan Medical School 
This study was undertaken to compare 
clinically the diuretic response resulting 
from benzylthiomethyl chlorothiazide, a 
newer substituted benzothiadiazine, with 
that obtained from chlorothiazide. The ef-
fect of each agent on body weight, urine 
volume, and urine sodium and potassium 
contents was observed. Patients received, 
in random order, one of these drugs or a 
placebo on each day of a consecutive 3 day 
period. All subjects were hospitalized; all 
had fluid retention meriting diuretic ther-
apy. Seventeen patients were studied (7 
had organic heart disease with congestive 
heart failure, 5 hepatic cirrhosis, 2 the 
nephrotic syndrome associated with dia-
betic nephropathy, 2 lymphoblastoma, and 
one idiopathic cyclical edema) . 
Methods 
A single oral dose of either 100 mg. hy-
drochlorothiazide or 100 mg. benzyl-
thiomethyl chlorothiazide, or a placebo tab-
Diuretic drugs supplied were 3-benzylthiomethyl chlo-
rothiazide (3-benzylthiomethyl-6-chloro-7 -sulfamyl-I,2,4,-
benzothiadiazine-l, I-dioxide) as P-1393 by Chas. Pfizer 
& Co., Inc., and hydrochlorothiazide (6-chloro-7 -sulfamyl-
3, 4-dihydro-I,2,4-benzothiadiazine-l, I-dioxide) as Hy-
drodiuril by Merck Sharp & Dohme Research Laboratories. 
let of identical size and shape, was given to 
each patient at 7:00 A.M. The amount of 
drug and the frequency of its administra-
tion were chosen for comparability rather 
than for maximal diuretic effectiveness. The 
composition of any tablet used was known 
neither by the physician giving it nor by 
the subject receiving it. The order of ad-
ministration of the three substances during 
the 3 day period was randomized to com-
pensate for any effect that one agent might 
have on the action of a second given the 
following morning. 
Each patient was given any additional 
necessary medication and had the same 
diet prescribed for at least 5 days prior to 
and during the 3 days of administration of 
the diuretic drugs, so that these factors 
would not affect this comparative study. 
Two subjects received a regular hospital 
diet, 5 a 200 mg. sodium diet, and 10 an 
800 mg. sodium diet daily. Seven patients 
were maintained on 0.1 Gm. digitalis daily. 
One patient received 1 Gm. potassium 
chloride 3 times each day. 
Twenty-four hour urine collections were 
divided into the first 6 hours after the drug 
was given (7: 00 A.M. to 1: 00 P.M.) and the 
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Table I. Urine volume, sodium and potassium excretion after a placebo, benzylthiomethyl 
chlorothiazide, and hydrochlorothiazide 
o to 6 hours 6 to 24 hours 
Patient Drug 
No. Diagnosis given Urine Sodium Potassium Urine Sodium Potassium 
volume content content volume content content 
(ml.) (mEq.) (mEq.) (ml.) (mEq.) (mEq.) 
1 Heart faiI ure Placebo 256 1.2 7.6 550 2.8 24.4 
BTM* 310 0.7 24.4 653 9.5 54.6 
Hydrot 132 11.1 2.0 580 8.8 48.0 
-----
2 Lymphoma Placebo 440 3.6 16.7 560 3.8 22.2 
BTM 470 3.1 14.1 753 6.5 35.5 
Hydro 610 7.2 26.7 400 3.1 15.4 
---
3 Hepatic cirrhosis Placebo 280 3.2 14.8 210 1.4 7.7 
BTM 74 0.7 4.4 375 2.6 16.6 
Hydro 420 19.8 24.6 810 24.1 47.5 
--- -----
----
4 Hepatic cirrhosis Placebo 340 2.6 24.8 400 3.0 25.7 
BTM 160 1.3 13.3 460 3.5 34.1 
Hydro 295 2.2 14.8 440 2.9 20.1 
--
5 Heart faiIure Placebo 170 1.7 15.3 400 4.5 40.6 
BTM 550 56.4 32.9 725 6.6 46.6 
Hydro 490 5.8 43.5 980 13.3 94.0 
--------------------------
6 Heart faiIlIre Placebo 160 6.8 15.1 1,210 11.1 53.7 
BTM 85 2.1 7.3 1,470 16.5 62.8 
Hydro 210 10.3 19.0 1,600 39.0 68.0 
--
----~ 
----
7 Lymphoma Placebo 46 3.3 8.7 540 72.7 78.0 
BTM 130 19.5 21.4 415 63.1 62.2 
Hydro 95 13.7 16.5 200 38.3 32.7 
---
8 Hepatic cirrhosis Placebo 190 14.7 13.4 390 32.4 36.3 
BTM 170 26.6 13.8 720 129.6 56.7 
Hydro 320 73.5 28.0 860 203.2 48.0 
---
9 Hepatic cirrhosis Placebo 510 36.8 14.5 230 29.3 9.4 
BTM 260 19.9 19.9 375 24.1 16.8 
Hydro 440 62.3 13.5 585 49.8 35.1 
------------
-------
----
10 Diabetic nephropathy Placebo 235 5.9 12.0 1,160 12.8 74.6 
BTM 310 12.3 20.7 1,250 24.9 104.9 
Hydro 480 20.9 63.5 1,955 47.7 134.8 
-----
---
11 Heart faiIure Placebo 510 2.8 25.0 1,375 8.4 63.3 
BTM 780 10.2 55.1 774 82.1 10.6 
Hydro 168 3.3 23.5 1,124 17.5 103.4 
--- ----~ ---~ 
12 Heart failllre Placebo 280 14.6 6.9 940 7.0 23.9 
BTM 218 2.0 18.7 950 9.8 65.0 
Hydro 580 52.6 60.3 1,980 101.3 105.0 
--- ---~ ------------------
13 Hepatic cirrhosis Placebo 555 74.9 26.0 378 34.9 28.7 
BTM 400 50.7 29.6 688 49.4 38.5 
Hydro 48 5.8 2.9 510 30.2 34.4 
---
---------------------------------------
14 Heart faiIlIre Placebo 165 3.1 16.8 980 75.7 98.0 
BTM 230 11. 9 23.0 135 5.8 16.5 
Hydro 200 15.0 20.0 740 29.0 68.5 
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Table I 
Continued 
Patient 
No. 
-
Diagnosis 
15 Cyclical edema 
16 Heart failure 
---
17 Diabetic nephropathy 
Mean 
± 
S.E.M.+ 
Drug 
given Urine 
volume 
(mt.) 
Placebo 410 
BTM 705 
Hydro 1,318 
Placebo 700 
BTM 410 
Hydro 715 
Placebo 645 
BTM 1,540 
Hydro 1,550 
Placebo 346±70 
BTM 402±29 
Hydro 475±39 
*BTM, 100 mg. benzylthiomethyl chlorothiazide. 
tHydro, 100 mg. hydrochlorothiazide. 
tS.E.M. = Standard error of mean. 
subsequent 18 hours (1:00 P.M. to 7:00 A.M. 
the following morning). Body weight was 
recorded at 7:00 A.M. each day, after void-
ing and prior to administration of drug. 
Urine volumes were measured and sodium 
and potassium contents deterrnined by 
Harne photometry. 
Results 
Calculated mean urine volumes and 
mean sodium and potassium excretions of 
all patients following administration of 
each diul'etic agent and the placebo are 
shown in Fig. 1. Values determined for in-
dividual patients are shown in Table 1. In 
cornparison with the mean 24 hour urinary 
output observed with the placebo (1,131 
ml. ), benzylthiomethyl chlorothiazide in-
creased mean urine volume by 119. ml., 
whereas hydrochlorothiazide induced a 303 
ml. increase in the same period of time. 
The diuresis l'esulting from both hydro-
chlorothiazide and benzylthiomethyl chlo-
rothiazide was greater within the first 6 
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o to 6 kours 6 to 24 kours 
Sodium Potassium Urine Sodium Potassium 
Gontent content volume Gontent Gontent 
(mEq.) (mEq.) (mi.) (mEq.) (mEq.) 
7.5 11.3 1,500 22.8 87.7 
40.2 32.3 855 30.6 43.3 
65.9 27.6 1,230 113.7 55.9 
--------
37.7 9.2 588 57.4 14.5 
55.4 12.7 1,350 109.9 39.3 
62.4 26.1 380 17.1 6.2 
----
17.8 32.3 1,950 17.0 73.0 
91.8 42.7 2,400 133.4 90.2 
89.9 62.0 1,930 48.3 65.4 
14.0±4.7 15.9 ± 1.7 785±46 23.4± 5.9 44.8±6.7 
23.8±6.3 22.7±3.1 848±41 41.6±11.0 46.7±6.2 
30.7±7.1 27.9±4.5 959±45 46.3±12.3 57.8±8.5 
hours than in the following 18 hours. The 
mean 24-hour weight loss was 1.04 pounds 
after benzylthiomethyl chlorothiazide, 1.12 
pounds after hydrochlorothiazide, and 0.58 
pound after placebo. 
Hydrochlorothiazide caused more natriu-
resis and kaliuresis than did benzylthio-
methyl chlorothiazide in the doses used. In 
thefirst 6 hours it increased mean sodium 
excretion 119 per cent and potassium excre-
tion 76 per cent above control vallIes. The 
accompanying increase in urine volume 
was 37 per cent. In the subseqllent 18 ho urs 
sodium output increased 98 per cent, po-
tassillm 29 per cent, and urine volllme 22 
per cent. During the entire 24 hours after 
hydrochlorothiazide was given the total 
sodium excretion was 103 per cent greater, 
total potassillm 41 per cent greater, and 
urine volllme 27 per cent greater than the 
mean val lies during the 24 hours following 
placebo administration. 
During the first 6 hours after benzylthio-
methyl chlorothiazide was given, sodium 
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Fig. 1. The mean total urine volume, sodium, and 
potassium excreted in the first 6 hour period (on 
the left), the subsequent 18 hour period (in the 
center), and the entire 24 hour period (on the 
right) after a placebo tablet (diagonal line col-
umn), 100 mg. 3-benzylthiomethyl chlorothiazide 
(white column), and 100 mg. hydrochlorothiazide 
( column of squares). Verticallines represent range 
of standard error of the mean. 
excretion rose 70 per cent, potassium out-
put 46 per cent, and urine volume 16 per 
cent above the me an control values. The 
next 18 hours showed a sodium increase of 
78 per cent, potassium of 4 per cent, and a 
volume rise of 8 per cent. In the entire 24 
hours after benzylthiomethyl chlorothiazide 
administration, total sodium excretion in-
creased 75 per cent, total potassium 14 per 
cent, and urine volume 12 per cent above 
the mean levels found when the placebo 
was given. 
These percentages are not absolute val-
ues as they are derived from means which, 
as shown in Fig. 1, have considerable 
ranges of standard error. They do afford 
a relative comparison of the two diuretic 
agents, however. If one directly compares 
the efficacy of these diuretic drugs, it is 
found that in the first 6 hours after ben-
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zylthiomethyl chlorothiazide administra-
tion, sodium excretion was 77 per cent of 
that seen after hydrochlorothiazide, potas-
sium was 81 per cent, and urine volume 
was 85 per cent. During the subsequent 18 
hours the comparable figure for sodium 
excretion was 90 per cent, potassium 81 
per cent, and urine volume 88 per cent. In 
the entire 24 hour period after benzylthio-
methyl chlorothiazide was given there was 
85 per cent as much sodium, 81 per cent as 
much potassium, and 87 per cent of the 
volume of urine excreted as there was after 
hydrochlorothiazide administration. 
Individual patients showed varying re-
sponses to these agents. Nine patients 
exhibited greater volume diuresis with hy-
drochlorothiazide; in 2 of these benzylthio-
methyl chlorothiazide had less effect than 
the placebo. Five subjects showed a greater 
diuretic response with benzylthiomethyl 
chlorothiazide; in 3 of these hydrochloro-
thiazide effected less response than the 
placebo. Three patients had little increase 
in urine volume after receiving either drug. 
Eleven patients demonstrated a greater 
natriuretic and kaliuretic effect of hydro-
chlorothiazide; in 3 of these there was less 
sodium and potassium excretion after ben-
zylthiomethyl chlorothiazide than after the 
placebo. Four subjects eliminated more 
sodium and potassium after receiving ben-
zylthiomethyl chlorothiazide; 2 of these 
excreted less sodium and potassium after 
hydrochlorothiazide than after the placebo. 
Two patients were relatively unresponsive, 
in respect to excretion of these ions, to the 
administration of both drugs. It should be 
emphasized that there was no correlation 
between the effectiveness of a particular 
agent and a specific disease process. No 
side effects from these drugs were observed 
in any of these patients. 
Discussion 
Administration of a placebo provides a 
control day during each 3 day period and 
allows evaluation of the effect of hydro-
chlorothiazide and benzylthiomethyl chlo-
rothiazide on urine volume and electrolyte 
Volurne 1 
Number 2 
excretion in each patient in relation to that 
seen when no diuretic agent is given. Since 
hydrochlorothiazide is a drug of known 
diuretic potency, it serves as a standard 
against which to judge benzylthiomethyl 
chlorothiazide.1,2 On a weight basis hydro-
chlorothiazide is 10 to 12 times as potent a 
diuretic agent as chlorothiazide; however, 
it is only one ninth as potent a carbonic 
anhydrase inhibitor.3 Its greater diuretic 
potency is due to a greater mercury-like 
effect. Benzylthiomethyl chlorothiazide also 
shows an electrolyte excretion pattern anal-
ogous to that of the mercurial diuretics.'" 
In evaluating a diuretic agent the most 
significant factor is its natriuretic effect, 
since sodium is the principal ionic constit-
uent of expanded extracellular volume. 
Sodium loss is necessary for the mobiliza-
tion of edema fluid. On the other hand, 
potassium loss is not desirable. A specific 
danger of potassium loss is the potentiation 
of digitalis toxicity. This has been reported 
during chlorothiazide therapy.4 The op-
timal objectives of diuretic therapy there-
fore are maximal sodium loss accompanied 
by minimal potassium loss. 
From the data presented here, based on 
dosage levels employed and the conditions 
"Based on infonnation supplied by Dr. D. G. Iezzoni, 
Chas. Pfizer & Co., Ine., Brooklyn, N. Y. 
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of this study, hydrochlorothiazide causes a 
greater increase in urine volume and more 
natriuresis and kaliuresis than does benzyl-
thiomethyl chlorothiazide. However, ben-
zylthiomethyl chlorothiazide is nearly as 
effective in its natriuretic and diuretic ac-
tions, being about 85 per cent as potent as 
is hydrochlorothiazide. The kaliuretic effect 
of benzylthiomethyl chlorothiazide was 
slightly less, although of similar magni-
tude, being 81 per cent of that caused by 
hydrochlorothiazide. In so far as these 
electrolytes are concerned, it appears that 
these drugs induce comparable excretory 
patterns. 
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